Bank of Montreal’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Bank of Montreal’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-237	Closed	-$6K	–	4190
2019 Q4	$6K	Buy	+237	New	+$5.02K	﹤0.01%	4658
2018 Q4	–	Sell	-760	Closed	-$19K	–	4681
2018 Q3	$19K	Sell	760 -13,155	-95%	-$323K	﹤0.01%	3717
2018 Q2	$336K	Sell	13,915 -15,436	-53%	-$416K	﹤0.01%	2524
2018 Q1	$853K	Buy	29,351 +8,165	+39%	+$231K	﹤0.01%	1991
2017 Q4	$504K	Buy	21,186 +8,014	+61%	+$202K	﹤0.01%	2275
2017 Q3	$356K	Buy	+13,172	New	+$320K	﹤0.01%	2422

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal's CNCR Position: Q1 2020 in Review

Bank of Montreal sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2020, closing a stake of 237 shares — an estimated $6K sold.

Bank of Montreal first reported a position in CNCR in Q3 2017 and held it in 6 quarters. The position peaked at $853K in Q1 2018. 18 funds tracked by Wall St. Rank hold CNCR as of Q1 2020.

Bank of Montreal reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2020 after selling out during the quarter.
Bank of Montreal sold 237 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2020, an estimated $6K.
Bank of Montreal first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q3 2017 and held it in 6 quarters.
Bank of Montreal's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $853K in Q1 2018.
18 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2020.

Based on Bank of Montreal's 13F filing for Q1 2020, filed 13 May 2020.